U.S. Markets close in 4 hrs 19 mins

Sucampo CEO search an unexpected positive, says Cantor

Sucampo Pharmaceuticals' second quarter results showed Amitiza demand grew in the U.S. despite competition, said Cantor. The firm views the unexpected announcement that the company is looking for a new CEO as a positive that may unlock more deal making opportunities and maintains its Buy rating and $11 price target on the stock.